<code id='86E306DF93'></code><style id='86E306DF93'></style>
    • <acronym id='86E306DF93'></acronym>
      <center id='86E306DF93'><center id='86E306DF93'><tfoot id='86E306DF93'></tfoot></center><abbr id='86E306DF93'><dir id='86E306DF93'><tfoot id='86E306DF93'></tfoot><noframes id='86E306DF93'>

    • <optgroup id='86E306DF93'><strike id='86E306DF93'><sup id='86E306DF93'></sup></strike><code id='86E306DF93'></code></optgroup>
        1. <b id='86E306DF93'><label id='86E306DF93'><select id='86E306DF93'><dt id='86E306DF93'><span id='86E306DF93'></span></dt></select></label></b><u id='86E306DF93'></u>
          <i id='86E306DF93'><strike id='86E306DF93'><tt id='86E306DF93'><pre id='86E306DF93'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:explore    Page View:977
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In